Clinical analysis on the relationship between gynecologic malignant neoplasms and metabolic syndrome
10.3760/cma.j.issn.1673-4904.2013.24.008
- VernacularTitle:妇科恶性肿瘤与代谢综合征关系的临床分析
- Author:
Zhimin HOU
;
Yanzhi LIU
- Publication Type:Journal Article
- Keywords:
Metabolic Syndrome X;
Gynecologic malignant neoplasms;
Insulin resistance;
Clinical characteristic
- From:
Chinese Journal of Postgraduates of Medicine
2013;36(24):20-23
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between gynecologic malignant neoplasms and metabolic syndrome (MS),in order to give a direction to the prevention and treatment of gynecologic malignant neoplasms.Methods A total of 359 cases of gynecologic malignant neoplasms (including 142cases of ovarian cancer,131 cases of endometrial cancer,86 cases of cervix cancer) were enrolled as study group,and 400 cases of gynecologic benign neoplasms were enrolled as control group.The general conditions,physical examination,fasting blood glucose,fasting insulin,homeostatic model assessment insulin resistance index (HOMA-IR),blood fat were compared between two groups.Clinical characteristics between two groups were compared.The occurrence of MS was counted.Results There was no significant difference in menarche age,onset age,gravidity and parity between two groups (P ＞0.05).The level of systolic pressure,diastolic pressure,body mass index,abdominal circumference,fasting blood glucose,fasting insulin,HOMA-IR,triacylglycerol in study group was higher than that in control group [(129 ± 13)mmHg (1mmHg=0.133kPa)vs.(112±14)mmHg,(87±11)mmHgvs.(75±8) mmHg,(26.7±2.8) kg/m2 vs.(22.2 ±2.1) kg/m2,(88 ±7) cm vs.(76 ±9) cm,(6.5 ±2.9) mmol/L vs.(4.7 ±0.9)mmol/L,(9.2 ± 4.7) mU/L vs.(5.2 ± 3.0) mU/L,3.9 ± 0.8 vs.3.1 ± 0.6,(3.21 ± 1.96) mmol/L vs.(1.56 ±1.22) mmol/L],and the level of high density lipoprotein cholesferol was lower than that in control group [(1.25 ± 0.51) mmol/L vs.(1.65 ± 0.47) mmol/L],and there were significant difference between two groups (P ＜ 0.05).The occurrence of MS in study group was 37.60％ (135/359),among of them,37.32％ (53/142)in ovarian cancer,43.51％(57/131) in endometrial cancer,29.07％ (25/86) in cervix cancer,which was higher than that in control group [12.25％ (49/400)],and there was significant difference (P ＜0.05).Conclusions The occurrence of MS in gynecologic malignant neoplasms is higher than that in gynecologic benign neoplasms,and there is a mutual promotion and influence of the relationship between gynecologic malignant neoplasms and MS.It suggests that there is a possible role of MS in the occurrence and development of gynecologic neoplasms,gynecologist should pay attention to it and control MS actively,those measures could make important significance of prevention and treatment for gynecologic malignant neoplasms.
